UNSPSC 51112506: Chlormethine hydrochloride

This classification denotes a nitrogen mustard compound with the molecular formula C5H11Cl2N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0MR697HHI, chemically known as 2,2-dichloro-n-methyldiethylamine but more generally known as chlormethine hydrochloride, which bears US NIH Compound Identifier 4033. European Medicines Agency schedules Chlormethine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01220MIG.

Most nations, for tariff and trade purposes, schedule chlormethine hydrochloride under HS 29211980. SMILES: CN(CCCL)CCCL.CL.

UNSPSC 51112506 Chlormethine hydrochloride is a Commodity code that nominally identifies a specific pharmaceutical active ingredient used in cancer chemotherapy, but recent state and local procurement activity under this code shows little relevance to the narrowly defined product scope. The Texas Health and Human Services Commission posted a Request for Information (RFI) in early April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program — a market intelligence and program-design exercise focused on pharmacy benefit management infrastructure, contracting models, and distribution channels rather than procurement of the chemical compound itself. The RFI solicits information from vendors about their capacity to establish direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers, negotiate based on net pricing models, and implement value-based or outcomes-based agreements with self-insured employers and government health plans.

The code shows minimal recent activity aligned with its commodity definition. The single recent opportunity identified — Texas HHS RFI No. HHS0017013, posted April 3, 2026 with the same-day response deadline — is exploratory in nature and does not commit to a specific contract award, budget, or timeline. The RFI functions as a preliminary market research tool to inform future formal procurement strategy rather than a binding solicitation for the pharmaceutical product itself. State and local procurement professionals evaluating this code should note that actual sourcing of chlormethine hydrochloride through state and local channels typically occurs via existing pharmacy benefit manager contracts, group purchasing organization agreements, or cooperative purchasing vehicles rather than direct commodity procurement notices. This code currently signals limited direct procurement activity and warrants monitoring only if pursuing pharmacy benefit or pharmaceutical supply-chain contracting opportunities at the state level.